Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Erlangen – page 16

390 clinical trials in Erlangen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erlangen at a glance
390
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

390 trials in Erlangen

Open in trial search

Conjunctivitis allergic

Not yet recruiting

Study on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Allergy Therapeutics (UK) Limited

Sjogren's syndrome

Not yet recruiting

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Vor Biopharma Inc.

Sjogren's syndrome

Not yet recruiting

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Evaluation of Upadacitinib for Reducing Ileal Strictures in Patients with Crohn’s Disease

Not yet recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:UZ Leuven

Chronic graft versus host disease

Not yet recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Neoplasm

Not yet recruiting

Study of sacituzumab govitecan versus investigator’s choice drug combination in patients with cancer of unknown primary after platinum‑based chemotherapy failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Autoimmune haemolytic anaemia+3

Not yet recruiting

Study of cc-97540 CD19‑Targeted NEX‑T CAR T in participants with chronic immune thrombocytopenia and autoimmune hemolytic anemia

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Colorectal adenocarcinoma

Not yet recruiting

Safety, Dose‑Finding and Feasibility Study of CD30/CEA CART in Patients with Liver Metastases from CEA‑Positive Colorectal Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Universitaetsklinikum Regensburg AöR

Acute lymphocytic leukaemia

Not yet recruiting

Study of blinatumomab plus drug combination in children and adolescents with acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Adenocarcinoma pancreas

Not yet recruiting

Efficacy and Safety of SIL204 Combined with Standard Chemotherapy in Patients with Locally Advanced Pancreatic Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Systemic scleroderma+1

Not yet recruiting

Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Systemic scleroderma

Not yet recruiting

Lebrikizumab in Adults with Moderate to Severe Localized Scleroderma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Erlangen

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, including studies of new therapies for HR-positive and HER2-negative variants. Additional research encompasses lung cancer and various lymphomas.

  • Advanced/Metastatic Breast Cancer Treatments
  • Non-small Cell Lung Cancer Therapy
  • Lymphoma Treatment Approaches

Studies evaluate novel therapeutic combinations and targeted treatments for improved patient outcomes.

02 Autoimmune Conditions

Comprehensive research into various autoimmune disorders, including lupus erythematosus, psoriasis, and systemic conditions. Studies focus on innovative therapeutic approaches.

  • Cutaneous Lupus Treatment
  • Plaque Psoriasis Management
  • Systemic Sclerosis Research

Trials aim to develop more effective treatments for chronic autoimmune conditions.

03 Neurological Disorders

Clinical investigations focusing on acute cerebral ischemic stroke and multiple system atrophy. Research emphasizes innovative therapeutic approaches for better patient outcomes.

  • Stroke Treatment Development
  • Multiple System Atrophy Management
  • Neurological Disease Interventions

Studies evaluate new therapeutic agents and treatment strategies for neurological conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.